EDAP TMS Secures €36 Million Credit Facility from the European Investment Bank to Accelerate Global Growth and Innovation

EDAP TMS Secures €36 Million Credit Facility from the European Investment Bank to Accelerate Global Growth and Innovation

(IN BRIEF) EDAP TMS SA has secured a €36 million credit facility from the European Investment Bank (EIB), supported by the European Commission’s InvestEU guarantee, to boost the global expansion of its Focal One® Robotic HIFU platform and fund new clinical developments. The agreement, structured in three tranches with variable interest rates, provides the company with long-term growth capital to enhance its leadership in non-invasive therapeutic technologies. EDAP CEO Ryan Rhodes highlighted the facility’s role in meeting global demand for advanced cancer and benign condition treatments, while EIB Vice-President Ambroise Fayolle reaffirmed the bank’s commitment to supporting European medtech innovation.

(PRESS RELEASE) LUXEMBOURG, 20-Oct-2025 — /EuropaWire/ — EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic and energy-based therapeutic technologies, has entered into a €36 million multi-tranche credit facility with the European Investment Bank (EIB), backed by a guarantee from the European Commission’s InvestEU program. This strategic financing will provide vital growth capital to support the company’s global expansion and ongoing innovation in non-invasive medical treatments.

The funding will primarily be used to advance the worldwide rollout of EDAP’s Focal One® Robotic High-Intensity Focused Ultrasound (HIFU) platform, which offers a non-invasive treatment alternative for both cancerous and benign conditions. It will also accelerate the development of new clinical indications for EDAP’s HIFU technology, including applications in urology and gynecology. The company expects to draw the first €11 million tranche in the fourth quarter of 2025.

“This Credit Facility provides EDAP with an important source of strategic growth capital,” said Ryan Rhodes, Chief Executive Officer of EDAP TMS. “It enables us to further expand the reach of Focal One® Robotic HIFU and meet the growing global patient demand for effective, non-invasive treatment options for both cancer and benign conditions.”

Ambroise Fayolle, Vice-President of the European Investment Bank, added: “Health and Life sciences are an important part of the European Investment Bank’s focus. The EIB is pleased to support the next development phase of Lyon-based EDAP and its innovative robotic HIFU platform designed to treat prostate cancer and endometriosis with non-invasive solutions.”

The partnership reflects EDAP’s long-term commitment to advancing robotic HIFU technology and strengthening its leadership in therapeutic innovation across urological, gynecological, and other medical applications.

Under the agreement, the €36 million Credit Facility will be made available in three tranches based on specific milestones:

• Tranche A: €11 million at an interest rate of 8%
• Tranche B: €12 million at an interest rate of 7%
• Tranche C: €13 million at an interest rate of 6%

Each tranche will mature five years from its disbursement date, with the EIB also receiving warrants allowing subscription to the company’s most preferential class of shares. Full details of the facility terms are available in EDAP’s latest filing with the U.S. Securities and Exchange Commission (SEC).

The collaboration with the EIB marks a key step in EDAP’s mission to transform the future of minimally invasive healthcare while expanding its impact in global medical markets.

About EDAP TMS SA

A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/.

About EIB

The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU’s long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide.

About InvestEU

The InvestEU programme provides the European Union with crucial long-term funding by leveraging substantial private and public funds in support of a sustainable recovery. It also helps to attract private investment for the European Union’s policy priorities, such as the European Green Deal and the digital transition. The InvestEU programme brings together under one roof the multitude of EU financial instruments currently available to support investment in the European Union, making funding for investment projects in Europe simpler, more efficient and more flexible. The programme has three components: The InvestEU Fund, the InvestEU Advisory Hub and the InvestEU Portal. The InvestEU Fund is implemented through financial partners that will invest in projects using the EU budget guarantee of €26.2 billion. The entire budget guarantee will back the investment projects of the implementing partners, increase their risk-bearing capacity and thus mobilise at least €372 billion in additional investment.

Media contact:
Andrea Morawski
a.morawski@eib.org
+352 4379 – 83427

Press Office
press@eib.org
+352 43791

SOURCE: European Investment Bank